Arabic Arabic English English French French German German
dark

The Australian TGA approves key label updates to Buvidal® for treatment of opioid dependence

Camurus AB announced that the Australian regulatory agency, the Therapeutic Goods Administration, has approved key label updates to Buvidal® Weekly and Buvidal® Monthly modified-release solutions for injection. Read More

Total
0
Shares
Leave a Reply

Your email address will not be published. Required fields are marked *

Previous Post

Kepro Acquires IMEDECS

Next Post

Eagle Pharmaceuticals Appoints Former FDA Official and Public Health Expert Dr. Luciana Borio to its Board of Directors

Related Posts
Total
0
Share